BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future.
Reform of the US patent system has been a long time coming. Year after year, it seems, US legislators get close to a consensus on satisfactory improvements to the patent system, only for their efforts to be scuppered by last-minute amendments, or other priorities, or just plain old disagreements. But this year, it might be different. A bill was approved earlier this year by the US Senate with broad bipartisan support. A similar bill is scheduled to be considered by the full House of Representatives in mid-June.
Assuming for now that the bill does get through in some form, what benefits would it bring to the biotechnology and life sciences industries? “BIO supports legislation that removes subjective elements of the patent system and provides a more reliable set of rules,” Greenwood says. “If patent reform is done in this way, the net effect will be positive.”
Specifically, provisions to allow the US Patent and Trademark Office (USPTO) discretion to set its fees and keep collected fees should increase its resources and make it more effective, while harmonisation with the global norm on first-to-file will “bring us closer to a time when the same examination doesn’t have to be done in 15 countries”. Additionally, provisions to tackle the big-business bugbear of false patent marking suits will be welcome.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
BIO, Interview, Jim Greenwood, USPTO, Healthcare, Biotechnology